Applied Spectral Imaging

Company Overview

Snapshot

Founded in February 1993, Applied Spectral Imaging operates with 51–200 employees. The company has raised $11 million across three funding rounds from three investors. In August 2025, Applied Spectral Imaging was acquired by ZYTOMICS, marking a significant exit for the company.

Business overview

Applied Spectral Imaging (ASI) develops automated imaging platforms for pathological analysis, providing end-to-end solutions for Pathology, Cytogenetics, and Research laboratories. Its core technology, GenASIs, combines image acquisition with computer-assisted analysis, enabling advanced diagnostics through powerful algorithms and customer-focused software. The company's product portfolio, including HiPath Pro, PathFusion, HiBand, HiFISH, CytoPower, and Rainbow, serves global markets within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.

Strategic signal

The acquisition of Applied Spectral Imaging by ZYTOMICS in August 2025 signals a strategic consolidation within the digital pathology market. This move indicates ZYTOMICS' intent to integrate ASI's advanced imaging and analysis capabilities, potentially expanding its market reach and enhancing its diagnostic offerings. For investors, this acquisition validates the value of automated microscopy imaging technologies and suggests a continued trend of strategic mergers in the health tech and life sciences sectors.

Company Intelligence Q&A

What was a significant corporate milestone for Applied Spectral Imaging?

Applied Spectral Imaging was acquired by ZYTOMICS in August 2025, marking a significant exit for the company and a strategic consolidation within the digital pathology market.

When did Applied Spectral Imaging launch its GenASIs Automated Imaging Platforms?

Applied Spectral Imaging announced the launch of its GenASIs Automated Imaging Platforms for Genetic and Pathology Analysis in December 2011.

What new products did Applied Spectral Imaging launch for the digital pathology market?

In October 2017, Applied Spectral Imaging launched two new products for the digital pathology market.

Which organizations partnered with Applied Spectral Imaging to bring medical innovation to pathology?

ARUP Laboratories and Applied Spectral Imaging partnered in November 2017 to bring medical innovation to pathology.

Did Applied Spectral Imaging receive regulatory clearance for any of its products?

In April 2015, Applied Spectral Imaging received South Korean Ministry of Food and Drug Safety (MFDS) Clearance for GenASIs™ HiPath IHC Family for HER2, ER, PR, and Ki67.